+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 6 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating the clinical effectiveness and safety of icotrokinra in adults with moderately to severely active Crohns disease, a long-term condition causing serious inflammation in the intestines. The study is a Phase 2b3 randomized, double-blind, placebo-controlled trial aiming to better understand how well icotrokinra works in treating this condition. Participants will receive one of several oral treatments daily during an initial 12-week induction phase either one of two doses of icotrokinra or a matching placebo. After Week 12, their response status will guide further treatment. Those responding to icotrokinra may be randomized to maintenance doses for up to 40 weeks, with some eligible to join a long-term extension study. Placebo recipients who respond may continue placebo or switch to icotrokinra under specific conditions. Throughout the trial, participants will undergo regular assessments to monitor clinical response, remission, and endoscopic healing at Weeks 12 and 40. Safety will be closely followed up to four weeks after the last dose. The study measures various outcomes including patient-reported remission, inflammatory markers, quality of life, and fatigue. Total participation may extend up to several months depending on treatment phase and eligibility for long-term follow-up.

Age: 18Years +All GendersPhase 2Phase 3
395 locations
P

Actively Recruiting

Gastrointestinal Stromal Tumor GIST is a type of soft tissue tumor that forms in the digestive system, often in the stomach or small intestine, caused by changes in certain proteins leading to uncontrolled cell growth. This research is evaluating the drug velzatinib GSK6042981 in adults with newly diagnosed metastatic or unresectable GIST, comparing it to the standard treatment imatinib to see if it can delay disease progression and assess safety and tolerability. Participants will be randomly assigned to receive either velzatinib or imatinib, with treatments given according to study protocols. The study will monitor each participant over time to compare the effects of these medications on tumor growth and patient health. Throughout the trial, participants will undergo regular assessments including imaging scans reviewed by independent central review, evaluations of tumor response, survival tracking, safety monitoring of side effects and vital signs, and quality of life questionnaires. The study will last for up to approximately 74 to 75 months, with ongoing evaluations to measure progression-free survival and other important outcomes.

Age: 18Years +All GendersPhase 3
93 locations
E

Actively Recruiting

Researchers are evaluating depemokimab as a treatment for adults with moderate to severe chronic obstructive pulmonary disease COPD who have type 2 inflammation and uncontrolled symptoms. This Phase 3 study aims to assess the effectiveness and safety of depemokimab when added to standard care for these patients. The focus is on reducing COPD exacerbations and improving respiratory health. Participants will be randomly assigned to receive either depemokimab or a placebo along with their usual COPD treatments. Depemokimab is given as a sterile liquid formulation, and the study compares its effects against placebo over a period of up to 104 weeks. Both groups continue their optimized inhaler therapy during the trial. During the study, participants will undergo regular assessments including lung function tests, symptom questionnaires like the COPD assessment test CAT, and monitoring of exacerbations. Researchers will measure outcomes such as the rate of moderate or severe exacerbations annually and changes in respiratory symptoms. Safety and overall health are closely followed throughout the two-year treatment period.

Age: 40Years - 80YearsAll GendersPhase 3
281 locations
E

Actively Recruiting

Researchers are studying adults with fibrosing interstitial lung disease ILD, excluding idiopathic pulmonary fibrosis IPF, who have been diagnosed within the last three years and may be at risk of developing progressive pulmonary fibrosis PPF. The trial aims to evaluate the effects of a medicine called nerandomilast in slowing lung function decline and disease progression in this group. Participants are randomly assigned to one of two groups one takes nerandomilast tablets, and the other takes placebo tablets that look identical but contain no medicine. The study lasts up to about 2 years and 4 months, during which participants take their assigned tablets regularly and undergo scheduled assessments to monitor their lung condition. Throughout the study, participants visit the study site regularly for tests including spirometry to measure forced vital capacity FVC and diffusing capacity of the lungs for carbon monoxide DLCO. High-resolution computed tomography HRCT scans track lung changes over time. Researchers compare these results between groups to assess treatment effects, while monitoring overall health and any side effects.

Age: 18Years +All GendersPhase 3
162 locations
L

Actively Recruiting

Researchers are evaluating the long-term safety and efficacy of the medicine GSK4527226 in people with early Alzheimers Disease, including those with mild cognitive impairment and mild dementia due to Alzheimers. This study is an open-label extension, meaning all participants will receive the same medicine. Participants must have completed the parent study called study 219867 to join this extension study. In this study, all participants will be given GSK4527226. The study will last up to 112 weeks, during which participants will receive the medicine and be monitored regularly. The open-label extension allows researchers to observe the effects of GSK4527226 over a longer period than in the original study. Participants will have regular assessments including monitoring for treatment-emergent adverse events, serious adverse events, and imaging abnormalities related to amyloid. Cognitive and functional abilities will be evaluated using several tests such as the Clinical Dementia Rating, AD Assessment Scale-Cognitive subscale, Mini-Mental State Exam, and others at multiple time points up to 104 weeks. The study includes safety monitoring and aims to gather detailed information about the medicines effects during long-term use.

Age: 50Years - 85YearsAll GendersPhase 2
33 locations
E

Actively Recruiting

Researchers are evaluating whether the medicine BI 1291583 can help adults and adolescents aged 12 to under 18 who have bronchiectasis and experience flare-ups, also called exacerbations. This Phase III randomized, double-blind, placebo-controlled study aims to assess the medicines safety, tolerability, and effect on reducing flare-ups in people with this condition. Participants are randomly assigned to one of two groups. One group takes BI 1291583 tablets, and the other takes placebo tablets that look the same but contain no active medicine. They take one tablet daily for up to 76 weeks, or about 1 year and 6 months. The study includes up to 10 in-person visits and around 13 phone calls with study staff during this time. During the study, participants regularly complete a symptom diary on a smartphone about their bronchiectasis. Study doctors monitor participants health, check for flare-ups, and record any unwanted effects. The main outcome measured is the annual rate of pulmonary exacerbations up to week 76, with other assessments including lung function tests and quality of life questionnaires. Participants stay in the study for up to 1 year and 8 months in total.

Age: 12Years +All GendersPhase 3
478 locations